Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing ...

Whilebiological drugs or biologics have improved the lives of many people with severe asthma, a new study shows that some ...

According to a real-world study, tezepelumab is an effective add-on biologic with a rapid onset of action for patients with both T2-high and T2-low severe asthma. The study was published ...

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of ...

The latest UK asthma guidelines1 clearly define the role of Fractional exhaled Nitric Oxide (FeNO) testing in both diagnosing ...

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

Researchers in the South West have discovered that patient feedback collected just weeks into starting biologic therapy – a treatment used for severe asthma – can predict the treatment’s ...

Western researchers recently attracted $15M in CIHR project grants, created “to support the bold ideas and innovative work of Canada’s health researchers.” ...

Asthma is one of the most common chronic respiratory conditions, with around 300 million people living with the condition ...

Research exploring novel therapies to fight against bladder cancer and a world-first asthma study are among 18 Western projects drawing more than $15 ...

Patients with moderate to severe atopic dermatitis experienced a 71% decrease in Eczema Area and Severity Index scores from baseline through 16 weeks with APG777, an anti-IL-13 antibody from Apogee ...